FDA warned Healthon over unapproved compounded semaglutide and tirzepatide sold online with false 'FDA-approved' and 'same as' claims.
What happened
In August 2025, FDA reviewed Healthon's website at healthon.com and found it offered compounded semaglutide and tirzepatide products. FDA said the site claimed these products had the 'same active ingredient' as Wegovy/Ozempic and Mounjaro/Zepbound, were 'clinically proven' for weight loss, and that the active ingredient was FDA-approved. FDA said compounded drugs are not FDA-approved and these claims are false or misleading, making the products misbranded.
What FDA found
Healthon's website claimed its compounded semaglutide and tirzepatide had the same active ingredient as FDA-approved Wegovy/Ozempic and Mounjaro/Zepbound, which is false or misleading.
FDCA § 502(a) [21 U.S.C. § 352(a)]; § 502(bb) [21 U.S.C. § 352(bb)]Healthon claimed its products were 'clinically proven' for weight loss, a misleading efficacy claim.
FDCA § 502(a) [21 U.S.C. § 352(a)]; § 502(bb) [21 U.S.C. § 352(bb)]Healthon said the active ingredient in its formula is FDA-approved, implying the compounded product is FDA-approved when compounded drugs are not.
FDCA § 502(a) [21 U.S.C. § 352(a)]; § 502(bb) [21 U.S.C. § 352(bb)]The misbranded products were introduced or delivered for introduction into interstate commerce.
FDCA § 301(a) [21 U.S.C. § 331(a)]Receipt in interstate commerce of misbranded drugs, and delivery or proffered delivery, is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, Healthon must send a written response to CDER's Office of Compounding Quality and Compliance describing steps taken to address the violations and prevent recurrence, with supporting documents. If it cannot complete the matter in that time, it must state the reason for delay and when it will do so.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compound pharmacies and their marketing partners
- companies making 'same as' or 'FDA-approved' claims for compounded drugs
This is a summary. Read the original letter on fda.gov.